GSK welcomes the publication of the 2012 Access to Medicines Index

Issued: Wednesday 28 November 2012, London UK

GSK welcomes the publication of the third Access to Medicines (ATM) Index, which measures the performance of the top 20 pharmaceutical companies on their efforts to improve access to medicines and healthcare in developing countries. GSK has been ranked top of the Index in 2012 for the third time of publishing, scoring highest in four categories including general access to medicine management, research and development activity, capability advancement and drug donation and philanthropy.

Commenting on the 2012 Index, GSK CEO Sir Andrew Witty said:
“GSK’s ranking in the ATM Index is a great acknowledgement of our commitment and to the work and dedication of people throughout GSK – whether the people working to manufacture the millions of doses of vaccines we ship to developing countries, those researching new treatments for diseases such as malaria, dengue and TB or our staff on the ground in Africa who help deliver greater access to medicines every day.

“Enabling greater access to medicines is firmly at the heart of our business. We are determined to do all we can to use our resources, knowledge and expertise to help improve people’s health and well-being no matter where in the world they live. We aim to do this while generating the returns we need to sustain our business and invest in further research.

“Over the past five years, this has led us to make fundamental changes to our business model – to ensure our medicines and vaccines are as available and affordable as possible, to encourage more research into neglected diseases, to support communities to strengthen their local health infrastructure and to form partnerships with governments, NGOs and other companies to help amplify our efforts.

“We recognise there is more we can do, and we will continue to challenge ourselves to adopt and deliver new ideas and approaches to improve lives around the world.”

The Access to Medicines Index is a major initiative of the Access to Medicines Foundation, an international not-for-profit organisation, established in 2004 and dedicated to improving access to medicines. The index ranks individual pharmaceutical companies on their efforts to enhance global access to medicines across seven categories: drug donation and philanthropy, capability advancement, patents and licensing, equitable pricing, research and development, public policy, and general access to medicines management.

The Index – the first of which was published in 2008, followed by a second in 2010 – provides an overall ranking of 20 pharmaceutical companies who are measured across a range of strategic and technical areas. It also analyses industry trends in commitments, transparency, performance and innovation.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

GlaxoSmithKline Enquiries: 

 

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

 

Sarah Spencer

+44 (0) 20 8047 5502

(London)

 

David Daley

+44 (0) 20 8047 5502

(London)

 

Catherine Hartley

+44 (0) 20 8047 5502

(London)

 

Alex Harrison

+44 (0) 20 8047 5502

(London)

 

 

 

 

US Media enquiries:

Stephen Rea

+1 215 751 4394

(Philadelphia)

 

Kevin Colgan

+1 919 483 2933

(North Carolina)

 

Melinda Stubbee

+1 919 483 2510

(North Carolina)

 

Mary Rhyne

+1 919 483 0492

(North Carolina)

 

Sarah Alspach

+1 202 715 1048

(Washington, DC)

 

Jennifer Armstrong

+1 215 751 5664

(Philadelphia)

 

 

 

 

Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543

(London)

 

Lucy Budd

+44 (0) 20 8047 2248

(London)

 

Tom Curry

+ 1 215 751 5419

(Philadelphia)

 

Gary Davies

+ 44 (0) 20 8047 5503

(London)

 

James Dodwell

+ 44 (0) 20 8047 2406

(London)

 

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

 

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.